Theratechnologies (TSE:TH) Sets New 1-Year High - What's Next?

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.38 during trading, with recent trading volume reported at 11,926 shares.
• The company has been downgraded from a "strong-buy" to a "hold" rating by Jones Trading as of July 3rd.
• Theratechnologies specializes in addressing the medical needs of HIV patients, offering two approved products: EGRIFTA and Trogarzo.

Theratechnologies Inc. (TSE:TH - Get Free Report) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$4.38 and last traded at C$4.38, with a volume of 11926 shares. The stock had previously closed at C$4.37.

Analysts Set New Price Targets

Separately, Jones Trading downgraded Theratechnologies from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 3rd.

Theratechnologies Stock Performance

The company has a debt-to-equity ratio of -293.92, a current ratio of 1.08 and a quick ratio of 0.64. The firm has a market cap of C$139.43 million, a price-to-earnings ratio of -49.47, a P/E/G ratio of -8.50 and a beta of 1.73. The firm has a fifty day simple moving average of C$3.86 and a two-hundred day simple moving average of C$3.16.

Theratechnologies Company Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.